|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Choudhury JH and Ghosh SK: Promoter
hypermethylation profiling identifies subtypes of head and neck
cancer with distinct viral, environmental, genetic and survival
characteristics. PLoS One. 10:e01298082015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen C, Mendez E, Houck J, Fan W,
Lohavanichbutr P, Doody D, Yueh B, Futran ND, Upton M, Farwell DG,
et al: Gene expression profiling identifies genes predictive of
oral squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev.
17:2152–2162. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Raudenska M, Sztalmachova M, Gumulec J,
Fojtu M, Polanska H, Balvan J, Feith M, Binkova H, Horakova Z,
Kostrica R, et al: Prognostic significance of the tumour-adjacent
tissue in head and neck cancers. Tumour Biol. 36:9929–9939. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dong JT, Lamb PW, Rinker-Schaeffer CW,
Vukanovic J, Ichikawa T, Isaacs JT and Barrett JC: KAI1, a
metastasis suppressor gene for prostate cancer on human chromosome
11p11.2. Science. 268:884–886. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vogt AB, Spindeldreher S and Kropshofer H:
Clustering of MHC-peptide complexes prior to their engagement in
the immunological synapse: Lipid raft and tetraspan microdomains.
Immunol Rev. 189:136–151. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gaugitsch HW, Hofer E, Huber NE, Schnabl E
and Baumruker T: A new superfamily of lymphoid and melanoma cell
proteins with extensive homology to Schistosoma mansoni antigen
Sm23. Eur J Immunol. 21:377–383. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ichikawa T, Ichikawa Y and Isaacs JT:
Genetic factors and suppression of metastatic ability of prostatic
cancer. Cancer Res. 51:3788–3792. 1991.PubMed/NCBI
|
|
10
|
Liu W, Iiizumi-Gairani M, Okuda H,
Kobayashi A, Watabe M, Pai SK, Pandey PR, Xing F, Fukuda K, Modur
V, et al: KAI1 gene is engaged in NDRG1 gene-mediated metastasis
suppression through the ATF3-NFkappaB complex in human prostate
cancer. J Biol Chem. 286:18949–18959. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Park JJ, Jin YB, Lee YJ, Lee JS, Lee YS,
Ko YG and Lee M: KAI1 suppresses HIF-1α and VEGF expression by
blocking CDCP1-enhanced Src activation in prostate cancer. BMC
Cancer. 12:812012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu Y, Yang JL, Markovic B, Jackson P,
Yardley G, Barrett J and Russell PJ: Loss of KAI1 messenger RNA
expression in both high-grade and invasive human bladder cancers.
Clin Cancer Res. 3:1045–1049. 1997.PubMed/NCBI
|
|
13
|
You J, Madigan MC, Rowe A, Sajinovic M,
Russell PJ and Jackson P: An inverse relationship between KAI1
expression, invasive ability, and MMP-2 expression and activity in
bladder cancer cell lines. Urol Oncol. 30:502–508. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Christgen M, Bruchhardt H, Ballmaier M,
Krech T, Länger F, Kreipe H and Lehmann U: KAI1/CD82 is a novel
target of estrogen receptor-mediated gene repression and
downregulated in primary human breast cancer. Int J Cancer.
123:2239–2246. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Christgen M, Christgen H, Heil C, Krech T,
Langer F, Kreipe H and Lehmann U: Expression of KAI1/CD82 in
distant metastases from estrogen receptor-negative breast cancer.
Cancer Sci. 100:1767–1771. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rowe A and Jackson P: Expression of
KITENIN aKAI1/CD82 binding protein and metastasis enhancer, in
bladder cancer cell lines: Relationship to KAI1/CD82 levels and
invasive behaviour. Oncol Rep. 16:1267–1272. 2006.PubMed/NCBI
|
|
17
|
Hashida H, Takabayashi A, Tokuhara T, Taki
T, Kondo K, Kohno N, Yamaoka Y and Miyake M: Integrin alpha3
expression as a prognostic factor in colon cancer: Association with
MRP-1/CD9 and KAI1/CD82. Int J Cancer. 97:518–525. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo XZ, Friess H, Shao XD, Liu MP, Xia YT,
Xu JH and Buchler MW: KAI1 gene is differently expressed in
papillary and pancreatic cancer: Influence on metastasis. World J
Gastroenterol. 6:866–871. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jee BK, Park KM, Surendran S, Lee WK, Han
CW, Kim YS and Lim Y: KAI1/CD82 suppresses tumor invasion by MMP9
inactivation via TIMP1 up-regulation in the H1299 human lung
carcinoma cell line. Biochem Biophys Res Commun. 342:655–661. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Takeda T, Hattori N, Tokuhara T, Nishimura
Y, Yokoyama M and Miyake M: Adenoviral transduction of MRP-1/CD9
and KAI1/CD82 inhibits lymph node metastasis in orthotopic lung
cancer model. Cancer Res. 67:1744–1749. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Uzawa K, Ono K, Suzuki H, Tanaka C,
Yakushiji T, Yamamoto N, Yokoe H and Tanzawa H: High prevalence of
decreased expression of KAI1 metastasis suppressor in human oral
carcinogenesis. Clin Cancer Res. 8:828–835. 2002.PubMed/NCBI
|
|
22
|
Farhadieh RD, Smee R, Ow K, Yang JL,
Russell PJ, Crouch R, Jackson P and Jacobson IV: Down-regulation of
KAI1/CD82 protein expression in oral cancer correlates with reduced
disease free survival and overall patient survival. Cancer Lett.
213:91–98. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miyazaki T, Kato H, Kimura H, Inose T,
Faried A, Sohda M, Nakajima M, Fukai Y, Masuda N, Manda R, et al:
Evaluation of tumor malignancy in esophageal squamous cell
carcinoma using different characteristic factors. Anticancer Res.
25:4005–4011. 2005.PubMed/NCBI
|
|
24
|
Yang X, Wei LL, Tang C, Slack R, Mueller S
and Lippman ME: Overexpression of KAI1 suppresses in vitro
invasiveness and in vivo metastasis in breast cancer cells. Cancer
Res. 61:5284–5288. 2001.PubMed/NCBI
|
|
25
|
Clark JD, Gebhart GF, Gonder JC, Keeling
ME and Kohn DF: Special report: The 1996 guide for the care and use
of laboratory animals. ILAR J. 38:41–48. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu WM and Zhang XA: KAI1/CD82, a tumor
metastasis suppressor. Cancer Lett. 240:183–194. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Skubitz KM, Campbell KD, Iida J and
Skubitz AP: CD63 associates with tyrosine kinase activity and
CD11/CD18, and transmits an activation signal in neutrophils. J
Immunol. 157:3617–3626. 1996.PubMed/NCBI
|
|
28
|
Lagaudrière-Gesbert C, Le Naour F,
Lebel-Binay S, Billard M, Lemichez E, Boquet P, Boucheix C,
Conjeaud H and Rubinstein E: Functional analysis of four
tetraspans, CD9, CD53, CD81, and CD82, suggests a common role in
costimulation, cell adhesion, and migration: Only CD9 upregulates
HB-EGF activity. Cell Immunol. 182:105–112. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Toyo-oka K, Yashiro-Ohtani Y, Park CS, Tai
XG, Miyake K, Hamaoka T and Fujiwara H: Association of a
tetraspanin CD9 with CD5 on the T cell surface: Role of particular
transmembrane domains in the association. Int Immunol.
11:2043–2052. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Malik FA, Sanders AJ and Jiang WG:
KAI-1/CD82, the molecule and clinical implication in cancer and
cancer metastasis. Histol Histopathol. 24:519–530. 2009.PubMed/NCBI
|
|
31
|
Jee BK, Lee JY, Lim Y, Lee KH and Jo YH:
Effect of KAI1/CD82 on the beta1 integrin maturation in highly
migratory carcinoma cells. Biochem Biophys Res Commun. 359:703–708.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Odintsova E, Sugiura T and Berditchevski
F: Attenuation of EGF receptor signaling by a metastasis
suppressor, the tetraspanin CD82/KAI-1. Curr Biol. 10:1009–1012.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schoenfeld N, Bauer MK and Grimm S: The
metastasis suppressor gene C33/CD82/KAI1 induces apoptosis through
reactive oxygen intermediates. FASEB J. 18:158–160. 2004.PubMed/NCBI
|
